Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

ESMO Open

article

P. Hofman¹  M. Ilié¹  E. Chamorey²  P. Brest³  R. Schiappa²  V. Nakache¹  M. Antoine⁴  M. Barberis⁵  H. Begueret⁶  F. Bibeau⁷  C. Bonnetaud¹  P. Boström⁸  P. Brousset⁹  L. Bubendorf^1,10  L. Carvalho^1,11  G. Cathomas^1,12  A. Cazes^1,13  L. Chalabreysse^1,14  M.-P. Chenard^1,15  M.-C. Copin^1,16  J.-F. Côté^1,17  D. Damotte^1,18  L. de Leval^1,19  P. Delongova^2,20  V. Thomas de Montpreville^2,21  A. de Muret^2,22  A. Dema^2,23  W. Dietmaier^2,24  M. Evert^2,24  A. Fabre^2,25  F. Forest^2,26  A. Foulet^2,27  S. Garcia^2,28  M. Garcia-Martos^2,29  L. Gibault^3,30  G. Gorkiewicz^3,31  D. Jonigk^3,32  J. Gosney^3,33  A. Hofman¹  I. Kern^3,34  K. Kerr^3,35  M. Kossai^3,36  M. Kriegsmann^3,37  S. Lassalle¹  E. Long-Mira¹  A. Lupo^1,18  A. Mamilos^2,24  R. Matěj^3,38  J. Meilleroux⁹  C. Ortiz-Villalón^3,39  L. Panico^4,40  A. Panizo^4,41  M. Papotti^4,42  P. Pauwels^4,43  G. Pelosi^4,44  F. Penault-Llorca^3,36  O. Pop^4,45  N. Poté^1,13  S.R.Y. Cajal^4,46  J.-C. Sabourin^4,47  I. Salmon^4,48  M. Sajin^4,49  S. Savic-Prince^1,10  H.-U. Schildhaus^5,50  P. Schirmacher^3,37  I. Serre^5,51  E. Shaw^5,52  D. Sizaret^2,22  A. Stenzinger^3,37  J. Stojsic^5,53  E. Thunnissen^5,54  W. Timens^5,55  G. Troncone^5,56  C. Werlein^3,32  H. Wolff^5,57  J.-P. Berthet^5,58  J. Benzaquen^5,59  C.-H. Marquette^5,59  V. Hofman¹  F. Calabrese^6,60 

[1] Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d"Azur;Epidemiology and Biostatistics Unit, Centre Antoine-Lacassagne, Université Côte d"Azur;Team 4, IRCAN, INSERM, CNRS, Centre Antoine-Lacassagne, Université Côte d"Azur;Department of Pathology, Hôpital Tenon;Unit of Histopathology and Molecular Diagnostics, Division of Pathology, IEO, European Institute of Oncology;Department of Pathology, University Hospital of Bordeaux;Department of Pathology, CHU de Caen, Université de Caen Normandie;Department of Pathology, Turku University Hospital;Department of Pathology, IUC-T-Oncopole, Inserm U1037 CRCT, Université de Toulouse;Institute of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel;Institute of Anatomical and Molecular Pathology and University Hospital, University of Coimbra;Institute of Pathology, Cantonal Hospital Baselland;Department of Pathology, Bichat Hospital, AP-HP, Inserm UMR 1152, Université de Paris;Department of Pathology, Groupement Hospitalier Est;Department of Pathology, University Hospital of Strasbourg;Institut de Pathologie, CHU Lille, Université de Lille;Department of Pathology, Institut Mutualiste Montsouris;Department of Pathology, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Inserm U1138, Université de Paris;Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University;Institute of Pathology, University Hospital Ostrava;Department of Pathology, Marie Lannelongue Hospital;Department of Pathology, University Hospital of Tours;Department of Pathology, Victor Babes University of Medicine and Pharmacy;Institute of Pathology, University of Regensburg;Department of Histopathology, St Vincent"s University Hospital, University College Dublin School of Medicine;Department of Pathology, University Hospital of Saint-Etienne;Department of Pathology, Centre Hospitalier;Department of Pathology, Hôpital Nord, AP-HM, Aix Marseille University;Pulmonary Pathology Department, Gregorio Marañon University Hospital;Department of Pathology, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris;Institute of Pathology, Medical University of Graz;Institute of Pathology, German Center for Lung Research, Biomedical Research in Endstage and Obstructive Lung Disease Hannover, Hannover Medical School;Liverpool University Hospitals, Royal Liverpool University Hospital;Department of Pathology, University Clinic Golnik;Department of Pathology, Aberdeen Royal Infirmary;Department of Pathology and Molecular Pathology, Centre Jean Perrin;Institute of Pathology, University Hospital Heidelberg, Heidelberg, and German Center for Lung Research;Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer Hospital and University Hospital Kralovske Vinohrady;Department of Pathology, Karolinska University Hospital;Unit of Pathology, Azienda Ospedaliera dei Colli;Department of Pathology, Complejo Hospitalario de Navarra;Department of Oncology, University of Torino;Centre for Oncological Research ,(CORE), University of Antwerp;Department of Oncology and Hemato-Oncology, University of Milan;Department of Pathology, University of Oradea;Department of Pathology, Vall d"Hebron University Hospital;Department of Pathology, Inserm 1245, Rouen University Hospital Normandy University;Department of Pathology, Erasme Hospital, Université Libre de Bruxelles;Department of Pathology, Emergency University Hospital, Carol Davila University of Medicine and Pharmacy;Institute of Pathology, University Hospital Essen;Department of Biopathology, Gui de Chauliac Hospital, Montpellier University Hospital;Department of Cellular Pathology, University Hospital Southampton NHS Foundation Trust;Department of Thoracic Pathology, Service of Pathology, University Clinical Centre of Serbia;Department of Pathology, Amsterdam University Medical Centres;Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen;Department of Public Health, University of Naples Frederico II;Laboratory of Pathology, Finnish Institute of Occupational Health;Department of Thoracic Surgery, FHU OnoAge, Louis Pasteur Hospital, University Côte d"Azur;Department of Pneumology, FHU OncoAge, Louis Pasteur Hospital, IRCAN, Université Côte d"Azur;Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Pathological Anatomy Section, University of Padova Medical School

关键词: COVID-19;    pathology;    biosafety;    lung cancer;    activity;   

DOI  :  10.1016/j.esmoop.2020.100024

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background This study evaluated the consequences in Europe of the COVID-19 outbreak on pathology laboratories orientated toward the diagnosis of thoracic diseases.Materials and methods A survey was sent to 71 pathology laboratories from 21 European countries. The questionnaire requested information concerning the organization of biosafety, the clinical and molecular pathology, the biobanking, the workload, the associated research into COVID-19, and the organization of education and training during the COVID-19 crisis, from 15 March to 31 May 2020, compared with the same period in 2019.Results Questionnaires were returned from 53/71 (75%) laboratories from 18 European countries. The biosafety procedures were heterogeneous. The workload in clinical and molecular pathology decreased dramatically by 31% (range, 3%-55%) and 26% (range, 7%-62%), respectively. According to the professional category, between 28% and 41% of the staff members were not present in the laboratories but did teleworking. A total of 70% of the laboratories developed virtual meetings for the training of residents and junior pathologists. During the period of study, none of the staff members with confirmed COVID-19 became infected as a result of handling samples.Conclusions The COVID-19 pandemic has had a strong impact on most of the European pathology laboratories included in this study. Urgent implementation of several changes to the organization of most of these laboratories, notably to better harmonize biosafety procedures, was noted at the onset of the pandemic and maintained in the event of a new wave of infection occurring in Europe.

【 授权许可】

CC BY|CC BY-NC-ND